



MITHRA SIGNS BINDING HEADS OF TERMS FOR COMMERCIALIZATION OF ESTELLE® IN SOUTH KOREA WITH WOMEN'S HEALTH SPECIALIST HYUNDAI PHARM

- **Mithra eligible for milestone payments, recurring revenues and further sales-related royalty payments, with production of Estelle® for the South Korean market at the Mithra CDMO¹**
- **With Estelle®, Hyundai Pharm aims to further expand its growing footprint in Women's Health**

Liège, Belgium, 5 June 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women's Health, today announced that it has signed a binding Heads of Terms agreement with Hyundai Pharm, a South Korean Women's Health leader, for an exclusive license to commercialize Estelle® in South Korea. Estelle® is Mithra's novel combined oral contraceptive (COC) product candidate currently in pivotal Phase III trials in Europe and Russia as well as in the US and Canada, with top line results expected in Q3 2018 and Q1 2019, respectively.

Under the terms of the agreement, Mithra will be eligible for milestone payments, Minimal Annual Quantities (MAQ) and further sales-related royalties. Moreover, Mithra will produce Estelle® for the South Korean market at its CDMO.

The South Korean contraceptive market is worth approximately EUR 36 million a year, with Combined Oral Contraceptives (COCs)² accounting for EUR 27 million.

Hyundai Pharm Co. Ltd. (listed on the Korean market as KR:004310), headquartered in Seoul, Korea, is a leading manufacturer and distributor of pharmaceutical products, health food drinks and medical equipment. The company was founded in 1965 and reported total revenues of USD 130 million in 2017. Women's Health is one of Hyundai Pharm's key focus areas, including a range of products for emergency contraception, morning sickness and Hormone Treatment (HT). The company has been steadily expanding its Women's Health franchise, and aims to launch Estelle® as a fifth-generation oral contraceptive in South Korea. Moreover, Hyundai Pharm is prepared to significantly invest in bringing Estelle® to market, with the clear intention to grow a still relatively small South Korean contraceptive market using Mithra's novel contraceptive.

François Fornieri, CEO of Mithra, commented: *"We are very pleased to have agreed terms with Hyundai Pharm for the commercialization of Estelle® in South Korea. With their increasing focus on Women's Health, we are confident that Hyundai Pharm is the best possible partner for the commercialization of Estelle®. Hyundai is a top three Women's Health company in Korea, and the fastest growing one, with a CAGR of over 21% over the last three years³.*

¹ Contract Development & Manufacturing organization

² IQVIA (IMS) Q3 2017; CAGR +9% (2013-2017)

³ Hyundai company presentation

“Following contracts with Fuji Pharma in Japan, Libbs in Brazil and Searchlight in Canada, we continue to deliver on our strategy to create key partnerships with Women's Health leaders around the world. We will continue to pursue this best-in-class approach as we select partners in the core territories of Europe and the US to maximize the potential of our blockbuster candidates, Estelle® for contraception and Donesta® for menopause.”

For more information, please contact:

Investor Relations

Sofie Van Gijssel, IR & VP of Strategy

+32 485 19 14 15

investorrelations@mithra.com

svangijssel@mithra.com

Press

Consilium Strategic Communications

Jonathan Birt, Philippa Gardner, Hendrik Thys

mithra@consilium-comms.com

+44 2 037 095 700

About Estelle®

Estelle® is Mithra's novel oral contraceptive product candidate composed of 15 mg Estetrol (E4), its unique native estrogen, and 3 mg DRSP. Currently, pivotal Phase III Estelle® trials (*E4 Freedom*) are ongoing in Europe and Russia as well as in the US and Canada, with top line results expected in Q3 2018 and Q1 2019, respectively.

The *E4 Freedom* studies are open-label single arm trials to assess the safety and efficacy of Estelle® in over 1,550 participants in Europe/Russia and approximately 2,000 participants in the US/Canada, over a period of 13 cycles. Patient enrolment has been completed for both pivotal studies.

About Hyundai

Hyundai Pham Co. Ltd. (listed on the Korean market as KR:004310), headquartered in Seoul, Korea, is a leading manufacturer and distributor of pharmaceutical products, health food drinks and medical equipment. The company has been founded in 1965, and reported revenues of USD 130m in 2017. The Hyundai team is committed to being a market creator, foreseeing unmet medical needs and pioneering new market opportunities. Women's Health is one of their key focus areas.

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO.

Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com